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ABSTRACT  In clinical medicine, the phenomenon of polypathy, as a particular object of investigation, was first put forth by French clinicians at the end of the 
19th century through the “arthritismus” doctrine. In the first half of the 20th century, German paediatricians singled out “syntropias,” which are combinations 
of diseases with common pathophysiological mechanisms, and “dystropias,” which are diseases that rarely co-occur in one individual. In the present paper, 
syntropy/dystropy is defined as a natural generic nonrandom phenomenon with an evolutionary-genetic basis. the genes involved in the development of syntropy 
are called “syntropic genes,” whereas the genes that co-participate in pathophysiological mechanisms and prevent the co-occurrence of particular phenotypes are 
called “dystropic genes.” Prospects for studying the genetic basis of this phenomenon are highlighted. the publicly available database HuGenet can be used in 
order to identify syntropic genes, as will be shown as examples in an analysis of cardiovascular diseases.
Keywords: syntropy, dystropy, syntropic and dystropic genes, genome, phenome, HuGenet. 
INTRODuCTION
Global epidemiological studies of human diseases have yielded 
plenty of results, among which three observations deserve 
special attention when considering polypathy and the phe-
nomenon of polymorbidity; that is, the situation in which an 
individual carries several diseases at the same time. First, only 
30 chronic multifactor diseases account for 65 % of all the dis-
eases human beings suffer from, accounting for morbidity and 
mortality rates in contemporary populations [1]. the risk of 
contracting such a multifactor disease in one’s lifetime is esti-
mated at 60 % [2] in Western populations. Secondly, polypathy 
is typical of the clinical state of a contemporary patient. In pa-
tients over 65 years of age, it is common to observe more than 
ten related diseases in clinical practice; the co-occurrence of 
diseases in women is more frequent than in men (this is true 
for all age groups) [3]. Finally, genetic epidemiology studies 
of common multifactor diseases point to the importance of 
inherited factors in their appearance and development. the 
role of genetic or inherited factors in determining the common 
phenotype of different diseases can vary, but even with low 
heritability indices (h2 = 20-30 %), the genetic factors that af-
fect vulnerability to infectious agents such as viruses, bacteria, 
helminths and parasites can be determined [4]. 
COMBINED DISEASES: SyNTROPy VS . DySTROPy
the term «polypathy» refers to any manner of combinations 
of diseases and syndromes in a single patient, including ac-
cidental maladies (traumas, iatrogenic illness, etc.). However, 
special forms of polypathy do exist and were combined un-
der the term “syntropy” offered by German paediatricians 
M. Pfaundler and L. von Seht. they defined syntropy as the 
“mutual disposition, attraction” of two disease conditions, 
whereas they refer to “mutual repulsion” as dystropy [5]. In 
the same authors’ opinion, a “syndrome” can also be regarded 
as syntropy, because it includes selective affinity of the traits 
it is made of. Another feature of the affinity of pathological 
conditions is synchrony, the appearance of at least two dis-
eases simultaneously.  
As proof that the syntropy concept is relevant, Pfaun-
dler and von Seht collected and analysed about 30 thousand 
medical records for children starting from 1906. they of-
fered an index of syntropy (S) showing how much the ob-
served number of combinations of the diseases differs from 
the number that would be expected at random and pro-
vided many examples of syntropias with a high S index. 
For instance, “congenital heart disease – joint rheumatism” 
(S = 58.55), “psychopathy – enuresis” (S = 15.31), “hyperthy-
rosis – nephropathy” (S = 4.94), and “nephritis – exudative 
erythema” (S = 4.49). 
recently, a number of papers have been published where-
by a similar idea was tested and proven using contemporary, 
sophisticated statistical methods [6-8]. they clearly dem-
onstrated a significantly more or significantly less frequent 
co-occurrence of certain diseases than would be expected at 
random. 
Actually, interest in polypathy was expressed even earlier, 
in the 19th century, through the concept of “arthritismus” by 
French clinician charles Bouchard, who defined arthritis-
mus as a specific disposition toward a group of diseases oc-
curring either in isolation or in different combinations in an 
individual or among many members of his or her family [9]. In 
the opinion of the author of the concept, these diseases had a 
common basic effect on metabolism: namely, they decreased 
it (bradytrophy). 
Along with syntropic interaction between diseases, antag-
onistic relationships, so-called “dystrophic” diseases, are de-
scribed. examples of dystropic diseases include lung tuberculo-
sis and mitral stenosis, type I diabetes mellitus and peptic ulcer 
disease, lymphoproliferative and myeloproliferative processes 
[3], as well as lung tuberculosis and bronchial asthma [9]. reVIeWS
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there are many well-known syntropic diseases, including 
cardiovascular diseases [10, 11]; immune-mediated diseases 
(allergic diseases, autoimmune diseases) [12-14]; endocrine 
diseases including the combination of diabetes mellitus, au-
toimmune thyroiditis, and celiac disease [15, 16]; and psychi-
atric diseases, such as major depressive disorders and bipolar 
disorder [17], narcotic and addictive states [18, 19]. 
to assess the genetic contribution to syntropy, it is impor-
tant to return to its definition: it is the natural generic non-
random phenomenon of combination of two or more patho-
logical states in an individual and his or her nearest relatives, 
with an evolutionary and genetic basis [20]. Syntropias com-
prise just part of all known polypathias. they include etiologi-
cally and pathogenetically linked combinations of diseases, 
unlike random combinations.
nonrandom combinations of pathologies in an individual 
and his or her relatives can highlight the common genes in-
volved in the disposition to separate diseases. Genetic studies 
of multifactor diseases strengthen our confidence that there 
are common genetic roots to such combinations (syntropias), 
notably when such combinations occur more often in fami-
lies of patients with these groups of diseases compared to the 
general population. 
In this aspect, we postulated that against the background 
of the huge number of human phenome characteristics one 
can carve out a fairly legible sector including a considerable 
number of interrelated pathological traits – syntropias – for 
which genetics is a worthy subject of investigation. Genes 
corresponding to such syntropic traits are called syntropic 
genes [20].
SyNTROPIC GENES (A GENERAL VIEW ON THE PROBLEM)
epidemiological studies of complex diseases in humans pro-
vide good examples of syntropias (cardiovascular diseases 
continuum, allergic diseases, autoimmune diseases). Yet, for 
all syntropias it is important to identify the groups of genes 
that will determine one or the other pathophysiological path-
ways and can help predict the risk of syntropy among car-
riers of one or other combinations of those genes. Physical 
clustering of susceptibility genes in the human genome has 
been shown for a number of diseases and traits [21-23]. How-
ever, syntropic genes do not necessarily belong to a cluster of 
physically linked genes, but rather represent a set of func-
tionally interacting genes dispersed throughout the human 
genome, co-regulated and involved in a common biochemical 
or physiological pathway. 
Autoimmune disorders were among the first groups of 
diseases studied from the point of view of common genetic 
determinants in their development. there are many com-
mon elements in the clinical phenotype of autoimmune dis-
orders, approaches to their therapy, population prevalence, 
gender ratio (75% of patients with autoimmune diseases are 
females), and occurrence in families. Becker K.G. et al. put 
forward a hypothesis assuming that, in some cases, clinically 
different autoimmune diseases can be controlled by a com-
mon set of susceptibility genes [21]. they performed a com-
parison of the linkage results from 23 published autoimmune 
or immune-mediated disease genome-wide scans in humans 
(multiple sclerosis, crohn’s disease, psoriasis, asthma, and 
type I diabetes) and animals (experimental autoimmune en-
cephalomyelitis, rat inflammatory arthritis, rat type I dia-
betes, murine type I diabetes, Bordetella pertussis-induced 
histamine sensitization, immunity to exogenous antigens, 
and murine system lupus erythematosus); non-autoimmune 
disorder genome scans were analyzed as well (type II diabe-
tes, schizophrenia, bipolar disorder, leptin-dependent obesi-
ty, and hypertension). It was shown that the majority (about 
65%) of human positive linkages for immune-mediated dis-
eases map non-randomly into 18 distinct clusters and over-
lapping susceptibility loci occur between different human 
immune diseases. A similar pattern was observed in experi-
mental autoimmune/immune disease models. A number of 
autoimmune candidate genetic loci from different diseases 
did not fall into identifiable clusters, and these singleton loci, 
in the author’s opinion, may be independent loci; they may 
contribute to disease specific susceptibility, tissue or organ 
tropism, or may be false positives. In the control group of 
nonimmune-mediated human diseases, linkage with auto-
immune/immune clusters was rare. 
the need to screen the «immunological genome» for de-
tection of the genetic basis of infectious, inflammatory, and 
autoimmune diseases was pointed out in the early 1990s [24]. 
A similar issue was formulated by geneticists in respect to 
the long-standing clinical observation of the existence of an-
other immunological syntropy including psoriasis, psoriatic 
arthritis, atopic dermatitis, and asthma. However, in the pre-
genomic period, it was established that psoriasis is a clear 
example of a th1-mediated disease (cellular immunity) con-
trolled by IFn-γ gene expression, unlike the th2-mediated 
diseases (humoral immunity), such as asthma, for which IL-4 
gene expression is important. Genomic studies of these dis-
eases confirmed this: asthma, at least partially, results from 
molecular-genetic mechanisms different from those involved 
in psoriasis. to date, multiple genome-wide linkage studies 
and a number of genome-wide association scans for asthma 
have been performed, and several genomic regions have 
been repeatedly identified, including those on chromosomes 
2q33, 5q23-31, 6p24-21, 11q12-13, 12q24-12, and 13q14-12. 
eight new asthma susceptibility genes have been discovered 
by positional cloning: ADAM33 (desintegrin and mellopro-
teinase-33), DPP10 (dipeptidyl peptidase-10), PHF11 (plant 
homeodomain finger protein-11), GPRA (G protein-coupled 
receptor for asthma), HLA-G (histocompatibility antigen), 
CYFIP2 (cytoplasmic fragile X mental retardation-inter-
acting protein 2), IRAKM (interleukin 1 receptor-associated 
kinase), and OPN3 (opsin-3) [25, 26]. It has been shown that 
asthma loci and atopic dermatitis loci indentified by genomic 
scans rarely overlap [12, 27]. At the same time, genome-wide 
linkage scans have identified multiple loci linked to atopic 
dermatitis and psoriasis and revealed shared susceptibility 
loci for these diseases on chromosomes 1q21, 3q21, 17q25 and 
20p12 [28]. Hence, in the syntropy including four diseases as-
sumed earlier, asthma genetically significantly differs from 
the other three disorders. 
certainly, the abovementioned premises are just a general 
conception of syntropy and its genetic basis (syntropic and 
dystropic genes). the genetic component of this phenomenon, 
noticed earlier, should be the subject of contemporary studies 
based on advances in molecular biology and genetics, as well 
as functional genomics and bioinformatics. Such concepts 54 | ActA nAturAe |  № 3 2009
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help advance the complex problem of defining the genetic 
basis of common multifactorial human diseases. 
A similar disease network hypothesis was expressed and 
exploited in a recent study by rzhetsky A. et al. [7]. they ana-
lysed 1.5 million patient records for 161 disorders and offered 
an approach that allowed to estimate the extent of genetic 
overlaps between the diseases. Based on the results, rzhet-
sky A. et al. concluded that “disease phenotypes form a high-
ly connected network of strong pairwise correlations” and 
speculated that this can be immediately applicable to genetic 
mapping studies involving multiple, apparently disparate 
phenotypes. 
SyNTROPIC GENES FOR CARDIOVASCuLAR 
DISEASE CONTINuuM
Based on the concepts and definitions presented above, we 
aimed to define syntropic genes for a well-known group of 
syntropic diseases – cardiovascular disease continuum (cDc), 
including coronary artery disease (cAD), arterial hyperten-
sion (AH), stroke, metabolic syndrome (MS), dislipidemia 
(DL), obesity, and noninsulin-dependent diabetes-mellitus 
(nIDDM).
the cDc concept was initially presented in 1991 [10]. this 
idea considers cardiovascular diseases (cVD) as a sequential 
line of events determined by multiple, related and unrelated 
risk factors, progressing over a number of physiological and 
metabolic pathways and resulting in the development of the 
final stage of a heart disease. the continuum members (dis-
eases and traits) overlap and interact as a sequence of dis-
crete and tandem states during the progression of cVD [10, 
11]. this context allowed us to refer this unity of pathological 
conditions to a syntropy.  
We used the publicly available research tool HuGe navi-
gator to identify the genes underlying the development of 
seven cDc diseases (as specified above). the HuGe naviga-
tor provides access to a continuously updated human genome 
epidemiology database that includes information on popula-
tion prevalence of genetic variants, gene-disease associations, 
gene-gene and gene-environment interactions, and the eval-
uation of genetic tests. It is based on the achievements of the 
Human Genome epidemiology network (HuGenet™), a vol-
untary, international collaboration focused on assessing the 
role of human genome variation in health and disease at the 
population level. Since 2001, HuGenet™ has maintained a da-
tabase of published, population-based epidemiologic studies 
of human genes extracted and curated from PubMed [29].
In the HuGenet database, the number of genes studied 
in relation to the seven cVDs varied between 162 for DL and 
466 for AH. HuGe navigator ranks these genes by score for 
a given gene estimated as the ratio of the number of studies 
showing positive results for an association to the total number 
of published studies.
to stress the strength of the associations between genes 
and diseases, we only considered genes with a score equal to 
or greater than 0.01. the maximum scores for different genes 
associated with the diseases analyzed were 4.1 for DL, 1.60 for 
cAD, 1.12 for AH, 1.02 for stroke, 1.01 for MS, 0.74 for obesity, 
and 0.36 for nIDDM.
twenty-one of the genes found were associated with all of 
the cDc diseases (table 1). certainly, the number of genes 
underlying any particular disease included in cDc syntropy 
is much higher. However, for total cDc syntropy, in accor-
dance with HuGenet data and ranking criteria, only these 
21 genes can be attributed to the control of the development 
and structure of cDc syntropy itself, and these genes can 
be called syntropic genes of cDc. two features merit special 
attention. First, most of these genes are well-characterized 
and have been studied at length. Secondly, they comprise 
the inherited basis of the pathophysiological continuum of 
mechanisms underlying the development of this syntropic 
disease group, including dysfunction in lipid metabolism, 
renin-angiotensin-aldosteron system, sympathoadrenal sys-
tem, inflammation, and endothelial function. 
the results of genetic association studies (GAS) are con-
troversial due to sample heterogeneity (ethnic variety, age 
and gender differences), relatively small sample sizes (mega-
studies have appeared only recently), and indistinct clinical 
criteria in disease group recruiting. taking this into account, 
it is generally assumed that GASs should be accompanied by 
meta-analysis, as well as genome-wide association studies 
(GWASs). these principles were taken into account in the 
development of HuGenet, and genes appearing in GWAS 
and meta-analysis receive higher coefficients.
Table 1 – Syntropic genes for cardiovascular disease continuum
Order 
number
Gene 
symbol Gene product chromosomal 
localisation
1 ABcA1 AtP-binding cassette  
transporter 1 9q22-q21
2 Ace Angiotensin I-converting 
enzyme 17q23
3 ADIPOQ Adipocyte-specific secretory 
protein 3q27
4 ADrB2 β2-adrenergic receptor 5q32-q34
5 AGt Angiotensinogen 1q42-q43
6 AGtr1 Angiotensin receptor 1 3q21-q25
7 APOA1 Apolyporpotein А1 11q23
8 APOe Apolyporpotein Е 19q13.2
9 cetP cholesteryl ester transfer 
protein 16q21
10 eSr1 estrogen receptor 1 6q25.1
11 GnB3 Beta-3 G-binding protein  12p13
12 IL6 Interleukin-6 7p21
13 LIPc Hepatice lipase c 15q21-q23
14 LPL Lipoprotein lipase 8p22
15 LtA Lymphotoxin-α 6p21.3
16 MtHFr Methylenetetrahydrofolate 
reductase 1p36.3
17 nOS3 endotelia nO-synthase 7q36
18 PPArG Peroxisome proliferator-
activated receptor-γ 3p25
19 SerPIne1 Plasminogen activator  
inhibitor 1 7q21.3-q22
20 SeLe Selectin e 1q23-q25
21 tnF tumor necrosis factor-α 6p21.3reVIeWS
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ninety-one meta-analysis studies carried out for 21 genes 
and seven diseases were found in HuGenet. the numbers 
vary for different diseases, and the maximum values found 
are for the MTHFR and APOE genes (18 and 13 studies, re-
spectively). no meta-analyses have been published so far for 
the SELE, ESR1, and SERPINE1 genes. Among the diseases 
considered, cAD, stroke, AH, and obesity were the most com-
mon subjects of meta-analysis: 28, 21, 17, and 13 studies, re-
spectively.
At the time of this study, in the HuGenet, there were 13 
meta-analyses for the APOE gene, and cAD and stroke. re-
cent analyses [30] included 203 studies for a period from 1970 
to 2007, providing ultimate proof of the significant association 
between genetic variants of the APOE gene and cAD and 
stroke. For carriers of the e4 allele, the risk of cAD develop-
ment is 20% higher than those without it, and the cholesterol 
levels in low-density lipoproteins increase in the following 
direction (in terms of the presence of the APOE allele): e2/e2, 
e2/e3, e2/e4, e3/e3, e3/e4, e4/e4. the odds ratio (Or) for 
cAD development in carriers of e4 is 1.06 (95% cI 0.99-1.13). 
In a review of 500 papers [31], a significant and direct associa-
tion between the APOE and strokes in Asians (chinese, Japa-
nese, Koreans)---but not in caucasians---was established. 
Also, the association of strokes with other genes (Ace I/D, 
MtHFr 677c/t) was confirmed. thus, three phenotypes of 
the cDc syntropy express association with APOE and the as-
sociation is confirmed by meta-analyses.
For the other gene subjected to numerous meta-analyses, 
MTHFR, the association with five cDc phenotypes (cAD, 
AH, stroke, nIDDM, obesity) and its c677t polymorphism is 
rather supported [32-36] than not [37]. It is notable that the 
MTHFR polymorphism is an independent risk factor for AH 
[38].
the association of the ACE gene with cVD has been stud-
ied for a long period of time, and a large body of data has been 
accumulated. However, meta-analyses for the gene and their 
disease groups have been initiated only recently. there are 
seven such publications in the HuGenet database. In the me-
ta-analysis of 118 studies, the I/D polymorphism of ACE was 
conclusively shown to be associated with cAD and nIDDM 
[39]; however, there are meta-analyses that cannot confirm 
this association [36, 40]. Meta-analysis of the other gene in the 
rennin-angiotensinogene system, AGT, showed significant 
association between its polymorphism M235t and cAD, AH, 
obesity, and stroke; in all cases, the 235t/t genotype is as-
sociated with increased risk of diseases [41, 42].
For the association of the LPL gene and cVDs, the results 
of meta-analyses are quite controversial. there are just seven 
such analyses, and they deal with separate multiple polymor-
phisms of the gene. the results of one meta-analysis study 
identified an association between the Asn291Ser mutation 
and cAD, nIDDM, and DL (hypertrigliceridemia and low 
level of cholesterol in high-density lipoproteins) [43]. A me-
ta-analysis in which, for the first time, a gene-gene interac-
tion between APOE and LPL was shown has been published 
[44]. According to this study, in co-carriers of АРОЕ* Е4 and 
LPL*447X (S447X polymorphism), Or for stroke and myo-
cardial infarction development was 2.2 (р = 0.01).
three genes critical for the development of inflammation 
were shown to be important for cDc syntropy: IL6, TNF, and 
LTA. For the LTA gene, only one meta-analysis is known (for 
cAD); however, for the IL6 and TNF genes, five and seven 
meta-studies are cited in HuGenet, respectively. IL6 was 
examined in meta-analyses for association with nIDDM and 
cAD and confirmed the lack of any association [45-47]. For 
the TNF gene, there are meta-analyses for all diseases in-
volved in the cDc syntropy, except for DL. the analysis of 
31 studies of MS and -308G/A polymorphism of TNF showed 
that -308A allele carriers show a 23% higher risk of obesity; 
they also have significantly increased systolic blood pressure 
and plasma insulin levels [48]. the same polymorphism shows 
stable association with cAD and stroke in Asians: genotype 
-308G/G carriers show a 40% lower risk of stroke than the 
others [49].
For the other cDc syntropic genes and phenotypes, there 
are very few meta-analyses, and it is important to study them 
further using this method. 
Based on the information on shared and non-shared genes, 
we conducted a hierarchical cluster analysis of the cDc syn-
tropy diseases to determine whether they have gene-based 
relationships. two tight clusters are seen; one is comprised of 
AH, cAD, stroke and DL, while the other is composed of MS, 
obesity, and nIDDM (Fig. 1). 
It seems reasonable that AH, cAD, stroke, and DL form 
a close cluster by shared susceptibility genes. this has been 
proven by Dzau V. et al. [11] in their paper presenting the 
cDc concept. For these four components of cDc, the over-
lap of basic pathways (lipid metabolism, rennin-angiotensin-
aldosterone and adrenergic systems, oxidative stress, and 
endothelial dysfunction) in the phenotype development is 
demonstrated [34, 41].
However, MS, obesity, and nIDDM have their common 
and specific features in pathogenesis. the common feature 
being that their leading pathway is insulin metabolism. nev-
ertheless, MS is distinguished by resistance to hyperinsulin-
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associated with them. MS – metabolic syndrome; NIDDM – non-insulin 
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ism and insulin, while nIDDM is characterized by the im-
paired pancreatic beta-cell function and insulin resistance [50, 
51]. these features can be attributed to the relations between 
MS, nIDDM, obesity, and the other cVDs studied, which are 
reflected in the cluster diagram.
the approach presented here can potentially be applied 
to any other syntropic disease group. Presumably, it could be 
interesting to analyse the genetic clustering of the plethora of 
human diseases for the purpose of building a generic system 
for their classification. 
A similar approach was used recently by torkamani A. 
et al. [8], who showed a high correlation between the SnPs 
significant in the GWAS for cAD, AH, and nIDDM, as well 
as for biporal disorder (BD) and a number of immune-me-
diated diseases. In particular, they showed that among the 
top-ranked (in terms of the statistical significance of their 
association with diseases) 1 000 SnPs, there are 57 shared 
by cAD and nIDDM, 81 shared by AH and nIDDM, and 63 
shared by AH and cAD. these genetic correlations between 
the diseases were highly significant. Also, strong correlation 
between the autoimmunity-related disorders rheumatoid ar-
thritis and insulin-dependent diabetes-mellitus was demon-
strated. Surprisingly, a strong genetic correlation of BD and 
cAD and nIDDM, as well as a strong correlation between AH 
and crohn’s disease – seemingly unrelated diseases – was 
observed. this suggests some unexpected links between these 
diseases and argues for the utility of a genetic correlation-
based approach for natural disease categorization. 
CONCLuSION
“Phenome” by analogy with the term “genome” is defined as 
the exact phenotypic representation of a species [52]. It in-
cludes the morphological, biochemical, physiological, and on-
togenetic characteristics of an organism. Phenomics seeks to 
define the extent of variability in the phenome but represents 
a major challenge. the view of a pathological phenotype from 
the point of view of nonrandom combination of morbid traits 
(syntropy) does not coincide with the clinical tradition of pay-
ing primary attention to a particular diagnosis, a nosology. In 
the syntropic approach, from the infinite number of traits of 
the phenome, a sampling of interrelated traits controlled by 
common genes is assumed. the way to identify such syntropic 
genes is not significantly different from what is done for the 
genetic analysis of any non-Mendelian trait. However, sub-
stantially larger population sample sizes will be required to 
achieve confidence in a gene-phene link. Moreover, unifica-
tion (standardisation) of a phenotype is critical, if very time-
consuming, and dependent on the clinicians and epidemiolo-
gists involved in ongoing epidemiological studies in different 
regions of the world. 
In this respect, it is also worth noting the very well-rec-
ognized phenomenon of pleiotropy, the multiple phenotyp-
ic effects of a single gene. A few recent studies discuss this 
problem in application to human diseases and put forth ideas 
similar to the concept of syntropy [53, 54]. Likely, pleiotropy 
is one of the basic factors of syntropy development. the sum 
of the pleiotropic effects of genes constitutes the physiologi-
cal fields of their action, which can be described as the gene’s 
network or, in a more common sense, as the biological net-
work. the overlap of the fields of action of the genes forms a 
meta-field, which is the basis for the development of a group 
of diseases bearing relation to these genes. Given the com-
mon genetic background based on the interaction between a 
limited set of genes, these diseases would have a tendency to 
cluster together, constituting a syntropy. At the same time, 
these diseases are phenotypically distinguishable, because 
different parts of the gene meta-field of action will have a 
conclusive significance for different diseases.
An increase in genetic association studies, both candidate-
gene-based and GWAS-based, is forecasted [39]. this prog-
nosis is based on the advances in the availability of mapped 
SnPs, finalisation of the HapMap Project, microarray-based 
genotyping technology development, and evolution of sta-
tistical and bioinformatical methods. However, looking for 
genetic markers for complex disease risk is not as straightfor-
ward as detecting phenotypic biomarkers of the disease risk 
currently used in clinical practice [55].
Actually, the Or attributable to most alleles associated 
with complex diseases both in GASs and GWASs rarely 
reaches a value of 1.15-1.50; usually, even weaker associations 
are detected, and their application to clinical practice is esti-
mated to be low [55]. However, it cannot be excluded that the 
weak effect is a consequence of the genetic and phenotypic 
heterogeneity of the studied population, when there are indi-
viduals showing higher effects of respective genes, too. tak-
ing this into consideration, it is suggested that a well-focused 
approach to the organization of the study will help detect 
stronger and more robust associations of alleles with patho-
logical phenotypes, for instance, in young patients, among 
persons with a definite family aggregation of the diseases, 
or in patients frequently hospitalized [56]. In our opinion, the 
analysis of common genes for a chosen syntropy offered an 
option for such a well-focused study, which is helpful in dis-
covering genes with strong effects and ranking them by their 
effect in relation to a pathophysiological continuum.  
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